KHKoji Higai

Koji Higai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Koji Higai has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Kojiro Matsumoto

    Department of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan

    19 shared publications
  • Yutaro Azuma

    Department of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan

    11 shared publications
  • Yuzo Imaizumi

    Department of Clinical Chemistry Faculty of Pharmaceutical Sciences Toho University Miyama 2-2-1 274-8510 Funabashi Chiba Japan

    4 shared publications
  • Hidenari Nagai

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Omorinishi 6-11-1, Ota-Ku, Tokyo 143-8541, Japan

    3 shared publications
  • Takanori Mukozu

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    3 shared publications
  • Teppei Matsui

    Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    3 shared publications

Latest Publications

  • Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study

    by Shusuke Uekusa, Maho Nemoto, Yuki Hanai, Misaki Nakashin, Arisu Miyagawa, Sachiko Yanagino, Yoshiki Arita, Takahiro Matsumoto, Kenji Nishizawa, Hidenari Nagai, et al.

    Introduction: Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used for the treatment of various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events, especially hypothyroidism. This study investigated the incidence of hypothyroidism due to LEN and the relationships between hypothyroidism incidence and patient demographics by analyzing clinical laboratory data from HCC patients treated with LEN. Methods: This was a single-center, retrospective study of HCC patients who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration. Results: In total, 61 patients with HCC were enrolled. High-grade hypothyroidism (CTCAE Grade 2–3) was found in 36.1% (22/61 patients). In high-grade hypothyroidism, eosinophil (EOSINO) count was significantly low (p = 0.029). The cutoff value of EOSINO count was estimated to be approximately 150/µL. The adjusted odds ratios of high-grade hypothyroidism for current smoking and EOSINO count <150/µL were 0.237 (95% confidence interval: 0.063–0.893) and 4.219 (95% confidence interval: 1.119–15.92), respectively. Conclusion: The results showed that noncurrent smoking and EOSINO count <150/µL are risk factors for LEN-induced high-grade hypothyroidism.


  • Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma

    by Hidenari Nagai, Makoto Amanuma, Takanori Mukozu, Kojiro Kobayashi, Hideki Nagumo, Kunihide Mohri, Go Watanabe, Naoyuki Yoshimine, Yu Ogino, Yasuko Daido, et al.

    Introduction: Previously, we reported that the tyrosine kinase inhibitor (TKI) sorafenib decreases serum levels of carnitine and reduces skeletal muscle volume. Moreover, others reported that TKIs might lead to cardiomyopathy or heart failure. Therefore, this study aimed to evaluate the effects of lenvatinib (LEN) on skeletal muscle volume and cardiac function in patients with hepatocellular carcinoma (HCC). Methods: This retrospective study included 58 adult Japanese patients with chronic liver diseases and HCC treated with LEN. Blood samples were collected before and after 4 weeks of treatment, and serum carnitine fraction and myostatin levels were measured. Before and after 4–6 weeks of treatment, the skeletal muscle index (SMI) was evaluated from computed tomography images and cardiac function was assessed by ultrasound cardiography. Results: After treatment, SMI, serum levels of total carnitine, and global longitudinal strain were significantly lower, but serum levels of myostatin were significantly higher. Left ventricular ejection fraction showed no significant change. Conclusion: In patients with HCC, LEN decreases serum levels of carnitine, skeletal muscle volume, and worsens cardiac function.


  • Open Access

    Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma

    by Hidenari Nagai, Takanori Mukozu, Kojiro Kobayashi, Akira Nogami, Hideki Nagumo, Kunihide Mohri, Go Watanabe, Makoto Amanuma, Naoyuki Yoshimine, Yu Ogino, et al.

    Introduction: Atezolizumab, an immune checkpoint inhibitor, plus bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), is an approved first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Immune checkpoint inhibitors are more effective in patients with HCC when administered with anti-VEGF drugs; however, these drugs affect host immunity. Lenvatinib is an anti-VEGF agent used to treat HCC; therefore, this study evaluated the effect of treatment of HCC with lenvatinib on host immunity in patients with chronic liver disease (CLD). Methods: We studied adult Japanese patients with CLD and unresectable HCC treated with lenvatinib at our hospital. Lenvatinib was administered for 4 weeks (8 mg/day for bodyweight 60 kg). Blood samples were collected at baseline and at 4 weeks of treatment and examined for immune-related changes. Results: Forty-three patients were enrolled in this study. We found a significant increase in T helper (Th) 1 cells following 4 weeks of lenvatinib treatment, although there was no significant difference in Th2 cells and regulatory T cells. We also found a significant increase in serum levels of TNF-alpha, soluble TNF-alpha receptor I, and endothelial growth factor following 4 weeks of lenvatinib treatment. Furthermore, an increase in Th1 cells and serum levels of TNF-alpha was found in patients with partial response. Conclusion: Lenvatinib might induce Th1-dominant host immunity in patients with CLD and unresectable HCC treatment in patients who showed a partial response. These changes in host immunity may be a biomarker in HCC patients treated with lenvatinib.


  • Open Access

    Docosahexaenoic Acid Suppresses Oxidative Stress-Induced Autophagy and Cell Death via the AMPK-Dependent Signaling Pathway in Immortalized Fischer Rat Schwann Cells 1

    by Yasuaki Tatsumi, Ayako Kato, Naoko Niimi, Hideji Yako, Tatsuhito Himeno, Masaki Kondo, Shin Tsunekawa, Yoshiro Kato, Hideki Kamiya, Jiro Nakamura, et al.

    Autophagy is the process by which intracellular components are degraded by lysosomes. It is also activated by oxidative stress; hence, autophagy is thought to be closely related to oxidative stress, one of the major causes of diabetic neuropathy. We previously reported that docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) induced antioxidant enzymes and protected Schwann cells from oxidative stress. However, the relationship between autophagy and oxidative stress-induced cell death in diabetic neuropathy has not been elucidated. Treatment with tert-butyl hydroperoxide (tBHP) decreased the cell survival rate, as measured by an MTT assay in immortalized Fischer rat Schwann cells 1 (IFRS1). A DHA pretreatment significantly prevented tBHP-induced cytotoxicity. tBHP increased autophagy, which was revealed by the ratio of the initiation markers, AMP-activated protein kinase, and UNC51-like kinase phosphorylation. Conversely, the DHA pretreatment suppressed excessive tBHP-induced autophagy signaling. Autophagosomes induced by tBHP in IFRS1 cells were decreased to control levels by the DHA pretreatment whereas autolysosomes were only partially decreased. These results suggest that DHA attenuated excessive autophagy induced by oxidative stress in Schwann cells and may be useful to prevent or reduce cell death in vitro. However, its potentiality to treat diabetic neuropathy must be validated in in vivo studies.


  • Open Access

    A patient with advanced hepatocellular carcinoma and portal vein tumor thrombosis who showed a complete response to lenbatinib despite the complication of destructive thyroiditis

    by Kojiro Kobayashi, Hidenari Nagai, Takanori Mukozu, Daigo Matsui, Teppei Matsui, Naoyuki Yoshimine, Makoto Amanuma, Yu Ogino, Yasuko Daido, Noritaka Wakui, et al.

    80歳台女性.右背部痛に対する腹部単純CT検査にて,肝右葉を占める巨大腫瘤を指摘され,当科へ紹介となった.各種画像検査の結果から,門脈本幹への浸潤を伴うportal vein tumor thrombosis(PVTT)を合併した巨大肝細胞癌(HCC)と診断し,lenvatinibを用いて治療を開始した.lenvatinib投与開始2カ月後の採血で,急激な血中free T3およびfree T4の上昇を認め,破壊性甲状腺炎と診断しthiamazole内服を開始した.その後甲状腺機能低下へ移行したのを確認し,thiamazoleからlevothyroxine sodium hydrateへ変更することにより甲状腺機能が正常化し,さらに腹部造影CT検査でHCCの縮小壊死を確認した.lenvatinibが破壊性甲状腺炎を誘発し,PVTT合併HCCに対して著効した例は貴重であると考え報告する.


  • Globo-A Binds to the Recombinant Natural Cytotoxicity Receptor NKp44

    by Kenichiro Ito, Ryo Shiraishi, Koji Higai

    Natural killer (NK) cells play an important role in tumor immunity and infection control. The natural cytotoxicity receptors (NCRs) NKp46, NKp44 and NKp30 are involved in the control of the activation of NK cells. Few reports have investigated the ligands of NCRs. We previously reported the NCRs binding affinity to heparin and glycosaminoglycans. We also showed that multimeric sialyl Lewis X-expressing transferrin, secreted by human hepatoma HepG2 cells, binds to NKp46 and NKp44, but not to NKp30. In this study, we investigated the binding between NCRs and glycolipids. The possible binding of glycolipids to NCRs was screened by microarray, using the recombinant extracellular domain of NKp46, NKp44 and NKp30 tagged with 6×His (rNKp46, rNKp44 and rNKp30). We found that rNKp44 binds to Globo-A. However, we did not detect the interaction between rNKp46 or rNKp30 and any of the glycolipids investigated. Direct binding assays supported the results of the microarray screening. Therefore, we concluded that Globo-A is a novel ligand for NKp44 but not NKp46 and NKp30, and showed differences in the ligand selectivity of NCRs.


  • Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from Artemisia princeps

    by Jie Zhang, Tatsunori Sasaki, Wei Li, Kazuya Nagata, Koji Higai, Feng Feng, Jian Wang, Maosheng Cheng, Kazuo Koike


  • Open Access

    Evaluation of 147 Kampo prescriptions as novel protein tyrosine phosphatase 1B (PTP1B) inhibitory agents

    by Toshihisa Onoda, Wei Li, Koji Higai, Kazuo Koike

    Protein tyrosine phosphatase (PTP) 1B, a negative regulator of the insulin and leptin signaling pathways, is currently considered a promising target for the development of novel therapeutic approaches used to treat insulin-resistant type 2 diabetes mellitus (IR-T2DM). In this study, we examined the PTP1B inhibitory activity of 147 Japanese prescription Kampo formulations to evaluate their potential for clinical application in IR-T2DM treatment.


  • Open Access

    Transcriptional Regulation of Fucosyltransferase 1 Gene Expression in Colon Cancer Cells

    by Fumiko Taniuchi, Koji Higai, Tomomi Tanaka, Yutaro Azuma, Kojiro Matsumoto

    The α1,2‐fucosyltransferase I (FUT1) enzyme is important for the biosynthesis of H antigens, Lewis B, and Lewis Y. In this study, we clarified the transcriptional regulation of FUT1 in the DLD‐1 colon cancer cell line, which has high expression of Lewis B and Lewis Y antigens, expresses the FUT1 gene, and shows α1,2‐fucosyltransferase (FUT) activity. 5′‐rapid amplification of cDNA ends revealed a FUT1 transcriptional start site −10 nucleotides upstream of the site registered at NM_000148 in the DataBase of Human Transcription Start Sites (DBTSS). Using the dual luciferase assay, FUT1 gene expression was shown to be regulated at the region −91 to −81 nt to the transcriptional start site, which contains the Elk‐1 binding site. Site‐directed mutagenesis of this region revealed the Elk‐1 binding site to be essential for FUT1 transcription. Furthermore, transfection of the dominant negative Elk‐1 gene, and the chromatin immunoprecipitation (CHIp) assay, supported Elk‐1‐dependent transcriptional regulation of FUT1 gene expression in DLD‐1 cells. These results suggest that a defined region in the 5′‐flanking region of FUT1 is critical for FUT1 transcription and that constitutive gene expression of FUT1 is regulated by Elk‐1 in DLD‐1 cells.